Form 4: Apogee CEO Sells Shares Under Pre-Arranged Plan

Apogee Therapeutics CEO Michael Henderson sold 20,000 shares of common stock on December 10, 2025, under a Rule 10b5-1 trading plan.

Summary

• Michael Thomas Henderson, Chief Executive Officer and Director of Apogee Therapeutics, Inc. (APGE), reported the sale of 20,000 shares of the company's common stock.
• The transactions occurred on December 10, 2025.
• The shares were sold in three separate transactions at weighted average prices of $74.88, $75.79, and $76.58 per share.
• These sales were executed pursuant to a Rule 10b5-1 trading plan, which was adopted on August 13, 2025.
• Following these transactions, Henderson's direct beneficial ownership of common stock is 1,212,987 shares.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a factual insider transaction (sale of shares) that was executed under a pre-arranged Rule 10b5-1 trading plan. Such plans are typically for personal financial planning and diversification, rather than being indicative of a change in the company's fundamental outlook or a reaction to new material non-public information, thus mitigating any negative sentiment often associated with insider sales.

Future Outlook

NA

Industry Context

NA

Key Dates

Recommendation

The filing reports a pre-scheduled sale of shares by the CEO under a Rule 10b5-1 plan. This type of transaction is generally not indicative of a change in the company's fundamental outlook or a signal for immediate investment action, as it's often for personal financial planning or diversification rather than a reaction to new material non-public information. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Apogee Therapeutics, APGE, Michael Henderson, CEO, Director, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Equity Transaction